SCHEMBL10280477

SCHEMBL10280477

CCC(CCNC(=O)c1cc(Cl)ccc1S)C(=O)Nc1cccnc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 1/20 0.48
CYP11B2 P19099 3/20 0.47
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
FFAR2 O15552 1/20 0.44
GRIK1 P39086 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
LRRK2 Q5S007 1/20 0.43
CYP11B1 P15538 1/20 0.42
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
SGMS2 Q8NHU3 3/20 0.41
NAMPT P43490 2/20 0.41
PKM P14618 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14987958 0.85 KCNMA1 (0.48) KCNMA1CYP11B2LMNAHPGDFFAR2
SCHEMBL10308272 0.79 EHMT2 (0.49) KCNMA1CYP11B2LMNAHPGDFFAR2
SCHEMBL823592 0.78 HDAC3 (0.56) KCNMA1CYP11B2LMNAKMT2AMEN1
SCHEMBL19592331 0.74 KMT2A (0.60) LMNAFFAR2KMT2AMEN1RAB9A
SCHEMBL18661183 0.72 NAMPT (0.60) HPGDKMT2AMEN1MAPTRAB9A
SCHEMBL24688163 0.70 LMNA (0.62) LMNAKMT2AMEN1MAPTRAB9A
SCHEMBL21755225 0.69 LMNA (0.56) LMNAFFAR2KMT2AMEN1RAB9A
SCHEMBL21507660 0.68 CYP11B2 (0.73) KCNMA1CYP11B2GRIK1KMT2AMEN1
SCHEMBL829775 0.66 EHMT2 (0.54) LMNAKMT2AMEN1RAB9ANPC1
SCHEMBL830026 0.66 EHMT2 (0.46) KMT2AMEN1MAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178783-A1 HDAC INHIBITORS LIXTE BIOTECHNOLOGY, INC. 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178783-A1 HDAC INHIBITORS HDAC3, HDAC4, HDAC7 KCNMA1 2959/4885CYP11B2 2940/4885LMNA 2276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.